Extended-release antiepileptic drugs: A comparison of pharmacokinetic parameters relative to original immediate-release formulations

Epilepsia

Volumn 54, Issue 1, 2013, Pages 28-35

  Leppik, Ilo E ^a,c   Hovinga, Collin A ^b  

^a MINCEP Epilepsy Care   (United States)

^b DELL INC   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Anticonvulsants; Epilepsy; Extended release preparations; Medication adherence; Pharmacokinetics

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DEPAKOTE DR; ETIRACETAM; LAMOTRIGINE; OXCARBAZEPINE; PARACETAMOL; PHENYTOIN; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM;

ATAXIA; CONFUSION; COORDINATION DISORDER; DIPLOPIA; DIZZINESS; DOSE RESPONSE; DRUG FORMULATION; DRUG RELEASE; DRUG TOLERABILITY; HUMAN; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; STEADY STATE;

ANTICONVULSANTS; CARBAMAZEPINE; DELAYED-ACTION PREPARATIONS; DRUG TOLERANCE; EPILEPSY; HUMANS; VALPROIC ACID;

EID: 84872061537     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12043     Document Type: Review

References (46)

1. Banerjee PN, Filippi D, Allen HW,. (2009) The descriptive epidemiology of epilepsy-a review. Epilepsy Res 85: 31-45.
2. Bialer M,. (2007) Extended-release formulations for the treatment of epilepsy. CNS Drugs 21: 765-774.
3. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T,. (2007) Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res 73: 1-52.
4. Blaszczyk B, Czuczwar SJ,. (2010) Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients. Neuropsychiatr Dis Treat 6: 145-150.
5. Canger R, Altamura AC, Belvedere O, Monaco F, Monza GC, Muscas GC, Mutani R, Panetta B, Pisani F, Zaccara G,. (1990) Conventional vs controlled-release carbamazepine: a multicentre, double-blind, cross-over study. Acta Neurol Scand 82: 9-13.
6. Center for Drug Evaluation and Research (2003) Guidance for industry-bioavailability and bioequivalence studies for orally administered drug products-general considerations. Available at: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf (Accessed November 13, 2012).
7. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL,. (1989) How often is medication taken as prescribed? A novel assessment technique. JAMA 261: 3273-3277.
8. Davis KL, Candrilli SD, Edin HM,. (2005) Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia 49: 446-454.
9. Depakote ER [package insert] (2010) Abbott Laboratories, North Chicago, IL.
10. Dutta S, Zhang Y, Selness DS, Lee LL, Williams LA, Sommerville KW,. (2002) Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers. Epilepsy Res 49: 1-10.
11. Endrenyi L, Tothfalusi L,. (2010) Do regulatory bioequivalence requirements adequately reflect the therapeutic equivalence of modified-release drug products? J Pharm Pharm Sci 13: 107-113.
12. Faught E, Duh MS, Weiner JR, Guerin A, Cunnington MC,. (2008) Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study. Neurology 71: 1572-1578.
13. Faught RE, Weiner JR, Guerin A, Cunnington MC, Duh MS,. (2009) Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study. Epilepsia 50: 501-509.
14. Garnett WR, Levy B, McLean AM, Zhang Y, Couch RA, Rudnic EM, Pellock JM, Belendiuk GW,. (1998) Pharmacokinetic evaluation of twice-daily extended-release carbamazepine (CBZ) and four-times-daily immediate-release CBZ in patients with epilepsy. Epilepsia 39: 274-279.
15. Hauser WA, Kurland LT,. (1975) The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia 16: 1-66.
16. Hauser WA, Annegers JF, Kurland LT,. (1993) Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 34: 453-468.
17. Jawad S, Yuen WC, Peck AW, Hamilton MJ, Oxley JR, Richens A,. (1987) Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Res 1: 194-201.
18. Jensen PK, Moller A, Gram L, Jensen NO, Dam M,. (1990) Pharmacokinetic comparison of two carbamazepine slow-release formulations. Acta Neurol Scand 82: 135-137.
19. Kardas P,. (2007) Comparison of patient compliance with once-daily and twice-daily antibiotic regimens in respiratory tract infections: results of a randomized trial. J Antimicrob Chemother 59: 531-536.
20. Kotsopoulos IA, van MT, Kessels FG, de Krom MC, Knottnerus JA,. (2002) Systematic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures. Epilepsia 43: 1402-1409.
21. Lamictal XR [package insert] (2011) GlaxoSmithKline, Research Triangle Park, NC.
22. Leppik IE,. (1988) Compliance during treatment of epilepsy. Epilepsia 29 (Suppl. 2): S79-S84.
23. Lhatoo SD, Johnson AL, Goodridge DM, MacDonald BK, Sander JW, Shorvon SD,. (2001) Mortality in epilepsy in the first 11 to 14 years after diagnosis: multivariate analysis of a long-term, prospective, population-based cohort. Ann Neurol 49: 336-344.
24. Manjunath R, Davis KL, Candrilli SD, Ettinger AB,. (2009) Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy. Epilepsy Behav 14: 372-378.
25. Miller AD, Krauss GL, Hamzeh FM,. (2004) Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine. Acta Neurol Scand 109: 374-377.
26. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM,. (2009) Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis 48: 484-488.
27. Pellock JM, Smith MC, Cloyd JC, Uthman B, Wilder BJ,. (2004) Extended-release formulations: simplifying strategies in the management of antiepileptic drug therapy. Epilepsy Behav 5: 301-307.
28. Powell G, Saunders M, Marson AG,. (2010) Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy. Cochrane Database Syst Rev CD007124.
29. Randinitis EJ, Buchanan RA, Kinkel AW,. (1990) Pharmacokinetic profile of a 300-mg extended phenytoin sodium capsule (Dilantin) formulation. Epilepsia 31: 458-464.
30. Reed RC, Dutta S, Cavanaugh JH, Locke C, Granneman GR,. (2006) Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations. Epilepsy Behav 8: 391-396.
31. Reed RC, Meinhold J, Dutta S, Liu W, Qiu Y,. (2010) What do the suffixes-XR, ER, Chrono, Chronosphere-really mean as it pertains to modified-release antiepileptic drugs? J Clin Pharm Ther 35: 373-383.
32. Rouits E, Burton I, Guenole E, Troenaru MM, Stockis A, Sargentini-Maier ML,. (2009) Pharmacokinetics of levetiracetam XR 500 mg tablets. Epilepsy Res 84: 224-231.
33. Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, Miners JO,. (2006) In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos 34: 1055-1062.
34. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC,. (2009) Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 15: e22-e33.
35. Smith MC, Centorrino F, Welge JA, Collins MA,. (2004) Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials. Epilepsy Behav 5: 746-751.
36. Steinhoff BJ,. (2009) Oxcarbazepine extended-release formulation in epilepsy. Expert Rev Clin Pharmacol 2: 155-162.
37. Steinhoff BJ, Wendling AS,. (2009) Short-term impact of the switch from immediate-release to extended-release oxcarbazepine in epilepsy patients on high dosages. Epilepsy Res 87: 256-259.
38. Stevens RE, Limsakun T, Evans G, Mason DH Jr,. (1998) Controlled, multidose, pharmacokinetic evaluation of two extended-release carbamazepine formulations (Carbatrol and Tegretol-XR). J Pharm Sci 87: 1531-1534.
39. Tegretol OROS Osmotic Release Delivery System Study Group. (1995) Double-blind crossover comparison of Tegretol-XR and Tegretol in patients with epilepsy. Neurology 45: 1703-1707.
40. Tompson DJ, Ali I, Oliver-Willwong R, Job S, Zhu L, Lemme F, Hammer AE, Vuong A, Messenheimer JA,. (2008) Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study). Epilepsia 49: 410-417.
41. Tothfalusi L, Speidl S, Endrenyi L,. (2008) Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets. Br J Clin Pharmacol 65: 110-122.
42. Trileptal [package insert] (2011) Novartis Pharmaceuticals Corporation, East Hanover, NJ.
43. Werz MA,. (2008) Pharmacotherapeutics of epilepsy: use of lamotrigine and expectations for lamotrigine extended release. Ther Clin Risk Manag 4: 1035-1046.
44. World Health Organization (2006) Neurological disorders: public health challenges. Available at: http://www.who.int/mental-health/neurology/neurodiso/ en/index.html (accessed August 14, 2012).
45. World Health Organization (2009) Epilepsy fact sheet no. 999. Available at: http://www.who.int/mediacentre/factsheets/fs999/en/index.html (Accessed August 14, 2012).
46. Yuen AW, Land G, Weatherley BC, Peck AW,. (1992) Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 33: 511-513.